Degradation of Bcl-xL by DT2216 is lethal to T-cell acute lymphoblastic leukemia.

被引：0
|
作者：
Jaiswal, Arunima S. [1 ]
Williamson, Elizabeth [2 ]
Hromas, Robert A. [2 ]
Zhou, Daohong [3 ]
机构：
[1] Hlth Career High Sch, San Antonio, TX USA
[2] Univ Texas Hlth Sci Ctr, San Antonio, TX USA
[3] Univ Florida, Gainesville, FL USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5654
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis
    Jaiswal, Arunima
    Jaiswal, Aruna
    Williamson, Elizabeth A.
    Gelfond, Jonathon
    Zheng, Guangrong
    Zhou, Daohong
    Hromas, Robert
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (01) : 89 - 95
  • [2] Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis
    Arunima Jaiswal
    Aruna Jaiswal
    Elizabeth A. Williamson
    Jonathon Gelfond
    Guangrong Zheng
    Daohong Zhou
    Robert Hromas
    Cancer Chemotherapy and Pharmacology, 2023, 91 : 89 - 95
  • [3] THE PROTAC DT2216 TARGETS CANCER BY PROMOTING BCL-XL DEGRADATION
    不详
    CANCER DISCOVERY, 2020, 10 (02) : 174 - 174
  • [4] Targeting Bcl-XL in Anaplastic Large Cell Lymphoma Using the Synthetic Proteolytic DT2216
    Medina, Edward
    Zhou, Daohong
    Zheng, Guangrong
    Hromas, Robert
    Kinney, Marsha
    Esparza, Javier
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1349 - 1349
  • [5] Targeting Bcl-XL in Anaplastic Large Cell Lymphoma Using the Synthetic Proteolytic DT2216
    Medina, Edward
    Zhou, Daohong
    Zheng, Guangrong
    Hromas, Robert
    Kinney, Marsha
    Esparza, Javier
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1349 - 1349
  • [6] CBFA2T3::GLIS2 pediatric acute megakaryoblastic leukemia is sensitive to BCL-XL inhibition by navitoclax and DT2216
    Gress, Verena
    Roussy, Mathieu
    Boulianne, Luc
    Bilodeau, Melanie
    Cardin, Sophie
    El-Hachem, Nehme
    Lisi, Veronique
    Khakipoor, Banafsheh
    Rouette, Alexandre
    Farah, Azer
    Theret, Louis
    Aubert, Leo
    Fatima, Furat
    Audemard, Eric
    Thibault, Pierre
    Bonneil, Eric
    Chagraoui, Jalila
    Laramee, Louise
    Gendron, Patrick
    Jouan, Loubna
    Jammali, Safa
    Pare, Bastien
    Simpson, Shawn M.
    Tran, Thai Hoa
    Duval, Michel
    Teira, Pierre
    Bittencourt, Henrique
    Santiago, Raoul
    Barab, Frederic
    Sauvageau, Guy
    Smith, Martin A.
    Hebert, Josee
    Roux, Philippe P.
    Gruber, Tanja A.
    Lavallee, Vincent -Philippe
    Wilhelm, Brian T.
    Cellot, Sonia
    BLOOD ADVANCES, 2024, 8 (01) : 112 - 129
  • [7] DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia
    He, Yonghan
    Koch, Raphael
    Budamagunta, Vivekananda
    Lv, Dongwen
    Khan, Sajid
    Zhang, Xuan
    Wiegand, Janet S.
    Zheng, Guangrong
    Weinstock, David M.
    Zhou, Daohong
    BLOOD, 2019, 134
  • [8] Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models
    Zhang, Qi
    Khan, Sajid
    Zhang, Xuan
    Kuruvilla, Vinitha Mary
    Ghotbaldini, Sanaz
    Wells, Julia
    Baran, Natalia
    Cai, Tianyu
    Han, Lina
    Ferrando, Adolfo
    Kim, Yong-Mi
    Zheng, Guangrong
    Zhou, Daohong
    Konopleva, Marina Y.
    BLOOD, 2019, 134
  • [9] DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
    Yonghan He
    Raphael Koch
    Vivekananda Budamagunta
    Peiyi Zhang
    Xuan Zhang
    Sajid Khan
    Dinesh Thummuri
    Yuma T. Ortiz
    Xin Zhang
    Dongwen Lv
    Janet S. Wiegand
    Wen Li
    Adam C. Palmer
    Guangrong Zheng
    David M. Weinstock
    Daohong Zhou
    Journal of Hematology & Oncology, 13
  • [10] Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs
    Broome, HE
    Yu, AL
    Diccianni, M
    Camitta, BM
    Monia, BP
    Dean, NM
    LEUKEMIA RESEARCH, 2002, 26 (03) : 311 - 316
12345